Pfizer: This Year’s Disaster Should Set The Stage For A Strong 2024


  • Pfizer has experienced a total return loss of nearly -40% so far in 2023, largely due to downshifts in demand for COVID-19 vaccines and antiviral products.
  • Shareholders faced additional challenges, including a dilutive $43 billion deal for Seagen, a tornado destroying its North Carolina production plant, and trouble with its weight-loss drug development plan.
  • Pfizer’s stock is now trading at a significantly lower valuation compared to peers, making it an attractive long-term investment with a high 5.7% dividend yield.

New York during the COVID-19 emergency.

Massimo Giachetti

2023 proved a year to forget for Pfizer (NYSE:PFE), and one to lick your wounds for shareholders experiencing a total return loss approaching -40%. My personal brokerage account suffered as a result, owning shares all the way down.

Analyst’s Disclosure: I/we have a beneficial long position in the shares of PFE, BMY either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

This writing is for educational and informational purposes only. All opinions expressed herein are not investment recommendations and are not meant to be relied upon in investment decisions. The author is not acting in an investment advisor capacity and is not a registered investment advisor. The author recommends investors consult a qualified investment advisor before making any trade. Any projections, market outlooks, or estimates herein are forward-looking statements based upon certain assumptions that should not be construed as indicative of actual events that will occur. This article is not an investment research report, but an opinion written at a point in time. The author's opinions expressed herein address only a small cross-section of data related to an investment in securities mentioned. Any analysis presented is based on incomplete information and is limited in scope and accuracy. The information and data in this article are obtained from sources believed to be reliable, but their accuracy and completeness are not guaranteed. The author expressly disclaims all liability for errors and omissions in the service and for the use or interpretation by others of information contained herein. Any and all opinions, estimates, and conclusions are based on the author's best judgment at the time of publication and are subject to change without notice. The author undertakes no obligation to correct, update or revise the information in this document or to otherwise provide any additional materials. Past performance is no guarantee of future returns.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Leave a Reply

Your email address will not be published. Required fields are marked *